https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00hjanustraumhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pnghjanustraum2024-06-17 06:30:432024-06-17 07:03:49Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2024-05-09 05:00:232024-05-09 05:00:23Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2024-04-24 15:00:492024-04-24 15:00:49Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2024-02-20 06:00:452024-02-20 06:00:45Acquisition of Freeline by Syncona Becomes Effective
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2023-10-25 01:01:132023-10-25 01:01:13Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2023-10-16 06:00:382023-10-16 06:00:38Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2023-10-04 06:00:412023-10-04 06:00:41Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
https://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.png00jeremiah@devisedesigns.comhttps://freeline.life/wp-content/uploads/Freeline_Logo_Red-300x66.pngjeremiah@devisedesigns.com2023-08-15 06:00:392023-08-15 06:00:39Freeline Reports Second Quarter 2023 Financial Results and Business Highlights